The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; Highlight Therapeutics; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).
 
Ignacio Melero Bermejo
Honoraria - PharmaMar
Consulting or Advisory Role - Alligator Bioscience; Amunix; AstraZeneca/MedImmune; BiolineRx; Boston Pharmaceuticals; Bright Peak Therapeutics; Bristol-Myers Squibb; Catalym; Curon Biopharmaceutical; Dompé farmaceutici; EMD Serono; F-star; Genmab; Genmab; GlaxoSmithKline; Gossamer Bio; Hookipa Pharma; ImmuneSensor Therapeutics; Merus; Moderna Therapeutics; Monopteros Therapeutics; MSD; Noxxon Pharma; Numab; Pieris Pharmaceuticals; Roche/Genentech; Sanofi; SERVIER; Shattuck Labs
Research Funding - Alligator Bioscience; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche/Genentech
 
Maria J. de Miguel
No Relationships to Disclose
 
Guzman Alonso
No Relationships to Disclose
 
Egle Ramelyte
Honoraria - BMS GmbH & Co. KG; Galderma; Lilly; MSD; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; Sanofi/Regeneron
Speakers' Bureau - BMS GmbH & Co. KG; Sanofi/Regeneron
Research Funding - Amgen (Inst)
Patents, Royalties, Other Intellectual Property - Contribution to UpToDate chapter update for Superficial acitic porokeratosis.
Travel, Accommodations, Expenses - Amgen; Sanofi
 
Markus Joerger
Consulting or Advisory Role - AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bristol-Myers Squibb (Inst); Innomedica (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Immunophotonics (Inst); Innomedica (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
 
Cyrus Sayehli
No Relationships to Disclose
 
Tanja Gromke
No Relationships to Disclose
 
Guillermo De Velasco
No Relationships to Disclose
 
Juan Martin Liberal
No Relationships to Disclose
 
Elena Garralda
Employment - Next Oncology
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Incyte; Janssen; MAB Discovery; Roche; Sanofi; Seagen; Thermo Fisher Scientific
Speakers' Bureau - Lilly; MSD; Novartis; Roche; Seagen; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Maria E. Rodriguez-Ruiz
No Relationships to Disclose
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Dagmar Hess
Stock and Other Ownership Interests - Novartis; Roche
 
Maria-Elisabeth Goebeler
Honoraria - AstraZeneca; Bristol-Myers Squibb; Janssen; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Catalym; GEMoaB; Janssen; Pfizer; Roche
 
Martin H. Schuler
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck Serono; Novartis; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Petra Fettes
Employment - Catalym
Stock and Other Ownership Interests - Amgen; CureVac
Patents, Royalties, Other Intellectual Property - Catalym
Travel, Accommodations, Expenses - Catalym
 
Kathrin Klar
Employment - Catalym
Travel, Accommodations, Expenses - Catalym
 
Frank Hermann
Employment - Catalym
Patents, Royalties, Other Intellectual Property - 4SC
Travel, Accommodations, Expenses - Catalym
 
Eugen Leo
Employment - Catalym; T-Knife
Leadership - Catalym; T-Knife
Stock and Other Ownership Interests - Catalym; T-Knife
Honoraria - Abalos GmbH
Patents, Royalties, Other Intellectual Property - Catalym; T-Knife
Travel, Accommodations, Expenses - Catalym; T-Knife